This article is more than 5 years old. Information may no longer be current.

Pfizer, Isis to collaborate on antisense drug development

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Isis Pharmaceuticals and Pfizer have entered into a multi-year drug discovery collaboration to identify “second-generation antisense drugs for the treatment of ophthalmic disease,” according to a press release from Isis.

Terms of the agreement call for Pfizer to pay Isis $1 million as a technology access fee. Isis will also receive royalties on the sales of drugs resulting from the collaboration. The agreement calls for Pfizer to be responsible for clinical development and commercialization of the antisense drugs.

Isis’ antisense technology platform allows researchers to “rapidly discover highly selective drugs to almost any gene target,” according to the release.